News

Inaphaea BioLabs has grown significantly since it was established in 2023. We have made great strides in commercialising our patient derived cell (PDC) bank and now offer cells for purchase and testing…

Inaphaea is pleased to confirm it is collaborating on a project using funds from The Open University’s Higher Education Innovation Fund (HEIF) to characterise the subtype and drug sensitivity of up to 12…

This news round-up covers our latest news and updates from September and October. It has been a busy month for Inaphaea, with our parent company ValiRx signing several agreements with CROs and…

Inaphaea BioLabs’ collaboration partner Inspiralis is a leading biotech specialising in DNA modifying enzymes and their substrates. The company supports preclinical development of anti-infective and anti-cancer compounds, either through the supply of…

Inaphaea BioLabs’ collaboration partner DefiniGEN provides technology to revolutionise liver models for drug efficacy and toxicology screening, utilising a platform that enables the large-scale generation of hepatocyte-like cells (Opti-HEP) with comparable functionality…

HistologiX is a leading GLP/GCP compliant CRO supporting tissue-based evaluation of biomarkers. The company’s experienced scientific team provides specialist histology, immunohistochemistry (IHC), immunofluorescence (IF), and in situ hybridisation (ISH) services including multiplex assay…

In recognition of Gynaecological Cancer Awareness Month, the Inaphaea team explores the potential of patient derived cells for gynaecological cancers.

Inaphaea BioLabs is pleased to confirm the execution of a revenue-bearing contract for the provision of patient derived oncology cell (PDC) based services with a US biotech company.  The contract is a…

From 3 to 6 June 2024, Inaphaea’s Head of Strategic Development, Dr Andrew Carnegie and our Scientific Consultant, Dr Mark Eccleston attended the BIO International Convention in San Diego with our partners…